Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Prognostic superiority of International Prognostic Index over [F-18]FDG PET/CT volumetric parameters in post-transplant lymphoproliferative disorder
Published in: EJNMMI Research
Access to document
10.1186/s13550-021-00769-8
document
BACKGROUND: Post-transplant lymphoproliferative disorders (PTLDs) are a spectrum of hematological malignancies occurring after solid organ and hematopoietic stem cell transplantation. [18F]FDG PET/CT is routinely performed at PTLD diagnosis, allowing for both staging of the disease and quantification of volumetric parameters, such as whole-body metabolic tumor volume (MTV) and total lesion glycolysis (TLG). In this retrospective study, we aimed to determine the prognostic value of MTV and TLG in PTLD patients, together with other variables of interest, such as the International Prognostic Index (IPI), organ transplant type, EBV tumor...
F Montes de Jesus, D Dierickx, V Vergote, W Noordzij, R A J O Dierckx, C M Deroose, A W J M Glaudemans, O Gheysens, T C Kwee
A Review on the Value of Imaging in Differentiating between Large Vessel Vasculitis and Atherosclerosis
Published in: Journal of personalized medicine
Access to document
10.3390/jpm11030236
document
Imaging is becoming increasingly important for the diagnosis of large vessel vasculitis (LVV). Atherosclerosis may be difficult to distinguish from LVV on imaging as both are inflammatory conditions of the arterial wall. Differentiating atherosclerosis from LVV is important to enable optimal diagnosis, risk assessment, and tailored treatment at a patient level. This paper reviews the current evidence of ultrasound (US), 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography (FDG-PET), computed tomography (CT), and magnetic resonance imaging (MRI) to distinguish LVV from atherosclerosis. In this review, we identified a total of eight studies...
Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16 alpha-[F-18]Fluoro-17 beta-Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer
Published in: Clinical Nuclear Medicine
Access to document
10.1097/RLU.0000000000003382
document
We offer an illustrative case about estrogen receptor (ER) imaging (also known as 16 alpha-[F-18]fluoro-17 beta-estradiol ([F-18]-FES) PET) and the detection of metastatic lesions in the dural region. We present a case of a woman with ER-positive metastatic breast cancer and high [F-18]-FES uptake in the dural region on PET imaging, without associated clinical symptoms. These lesions were missed on [F-18]-FDG PET because of physiological [F-18]-FDG uptake in the brain. This case highlighted some difficulties in the interpretation of imaging of brain metastases and demonstrated the added value...
An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-021-05198-2
document
Background MR is an important imaging modality for evaluating musculoskeletal malignancies owing to its high soft tissue contrast and its ability to acquire multiparametric information. PET provides quantitative molecular and physiologic information and is a critical tool in the diagnosis and staging of several malignancies. PET/MR, which can take advantage of its constituent modalities, is uniquely suited for evaluating skeletal metastases. We reviewed the current evidence of PET/MR in assessing for skeletal metastases and provided recommendations for its use. Methods We searched for the peer reviewed literature related...
Jad S. Husseini, Barbara Juarez Amorim, Angel Torrado-Carvajal, Vinay Prabhu, David Groshar, Lale Umutlu, Ken Herrmann, Lina Garcia Canamaque, Jose Ramon Garcia Garzon, William E. Palmer, Pedram Heidari, Tiffany Ting-Fang Shih, Jacob Sosna, Cristina Matushita, Juliano Cerci, Marcelo Queiroz, Valdair Francisco Muglia, Marcello H. Nogueira-Barbosa, Ronald J. H. Borra, Thomas C. KweeAndor W. J. M. Glaudemans, Laura Evangelista, Marco Salvatore, Alberto Cuocolo, Andrea Soricelli, Christian Herold, Andrea Laghi, Marius Mayerhoefer, Umar Mahmood, Ciprian Catana, Heike E. Daldrup-Link, Bruce Rosen, Onofrio A. Catalano
Value of [F-18]-FES-PET to solve clinical dilemmas in breast cancer patients: A retrospective study
Jorianne Boers, Naila Loudini, Celina L. Brunsch, Sylvia A. Koza, Erik F. J. de Vries, Andor W. J. M. Glaudemans, Geke A. P. Hospers, Carolina P. Schroder